CVRx, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CVRX | NSPR | ECOR | ACARIX.ST | VPT.V | AMIX | |
|---|---|---|---|---|---|---|
| Market cap | 42.09M | 36.31M | 75.73M | 204.68M | 13.50M | 3.16M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.8 | -1.6 | -15.3 | — | — | -0.2 |
| Price/book | 2.1 | 1.2 | -27.1 | 4.7 | -3.5 | 0.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −85.90% | −68.72% | +52.53% | −33.08% | −20.00% | −90.53% |
| Today | +14.49% | +20.47% | +16.18% | −8.23% | −6.67% | −3.01% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.
Latest news
All CVRX news ›CVRx Appoints John Landry as Chief Financial Officer
MINNEAPOLIS, Sept. 21, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ('CVRx'), a commercial-stage medical device company focused on develop... CVRx Appoints John Landry as Chief Financial Officer MINNEAPOLIS, Sept. 21, 2026 (GLOBE…
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CVRx (CVRX), Butterfly Network (BFLY) and Viridian Therapeutics (VRDN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on CVRx (CVRX), Butterfly Network (BFLY) and Viridian Therapeutics (VRDN). In a report released today, Matthew O’Brien from Piper Sandler reiterated a Hold…
Analysts Conflicted on These Healthcare Names: Novo Nordisk (NVO) and CVRx (CVRX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO) and CVRx (CVRX). In a report released yesterday, Evan Seigerman from BMO Capital maintained a Hold rating on Novo Nordisk,…
CVRx, Inc. (NASDAQ:CVRX) Stock Has Consensus Target Price of $4.30
CVRx, Inc. (NASDAQ:CVRX – Get Free Report) has been assigned an average rating of “Hold” from the six research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell…
Lake Street Remains a Hold on CVRx (CVRX)
In a report released today, Frank Takkinen from Lake Street reiterated a Hold rating on CVRx, with a price target of $3.50. Takkinen covers the Healthcare sector, focusing on stocks such as Avita Medical, TELA Bio, and CVRx. According to…
CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
Barostim will be featured across eight events at HFSA, including late-breaking clinical data, a rapid-fire session, posters and podium sessions. BENEFIT-HF, the landmark clinical trial initiated earlier this year evaluating Barostim in an…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com5
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.